X
[{"orgOrder":0,"company":"Kartos Therapeutics","sponsor":"Illumina","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Illumina and Kartos Therapeutics Announce New Oncology Partnership to Develop an NGS-Based TP53 Companion Diagnostic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Kartos Therapeutics","sponsor":"Tempus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tempus Announces Companion Diagnostic Collaboration with Kartos Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Kartos Therapeutics
Filters
Companies By Therapeutic Area
Details:
Kartos is collaborating with Tempus to use the xT assay, a 648-gene panel, to identify patients with TP53 wild-type (TP53WT) Merkel cell carcinoma (MCC) who may benefit from treatment with KRT-232 (navtemadlin, a small molecule MDM2 inhibitor).
Lead Product(s):
Navtemadlin
Therapeutic Area: Oncology
Product Name: KRT-232
Highest Development Status: Phase II
Product Type: Small molecule
Recipient:
Tempus
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
October 06, 2022
Details:
The initial focus of the collaboration will be the co-development of multiple CDx claims in blood cancers for Kartos’ KRT-232, a potent and selective oral MDM2 inhibitor that activates p53 to drive tumor cell death in TP53 wild-type cancers.
Lead Product(s):
Navtemadlin
Therapeutic Area: Oncology
Product Name: KRT-232
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Illumina
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
April 24, 2021